Maria Jesús Vidal

Grup de recerca

Genòmica translacional i teràpies dirigides en tumors sòlids Accredited researcher (R3A)

mjvidal@clinic.cat 0000-0003-1992-5727

Publicacions destacades

Sentinel node after NeoAdjuvancy in node-positive breast cancer. SANA multicentric study

Autors:
Rosello IV; Vidal-Sicart S; Sánchez N; Algarra XC; Torras I;

(...)

Muñoz M; Prat A; Farre BG; Marsical A; Vargas IA.

Referència: European Journal Of Cancer 2020.
Efficacy and Safety of Trastuzumab Emtansine Plus Capecitabine vs Trastuzumab Emtansine Alone in Patients With Previously Treated ERBB2 (HER2)-Positive Metastatic Breast Cancer: A Phase 1 and Randomized Phase 2 Trial

Autors:
Cortes, Javier; Dieras, Veronique; Lorenzen, Sylvie; Montemurro, Filippo; Riera-Knorrenschild, Jorge;

(...)

Vidal, Maria; Irahara, Natsumi; Wohlfarth, Christine; Aout, Mounir; Gelmon, Karen.

Referència: Jama Oncology 2020.
Frequency and spectrum of PIK3CA somatic mutations in breast cancer

Autors:
Martínez-Sáez, O; Chic, N; Pascual, T; Adamo, B; Vidal, M;

(...)

Muñoz, M; Prat, A; Martínez, D; Galván, P; Martinez, A.

Referència: Breast Cancer Research 2020.
HER2-enriched subtype and pathological complete response in HER2-positive breast cancer: A systematic review and meta-analysis

Autors:
Schettini, F; De Placido, S; Pascual, T; Bráso-Maristany, F; Galván, P;

(...)

Schiff, R; Veeraraghavan, J; Rimawi, MF; Osborne, CK; Carey, LA.

Referència: Cancer Treatment Reviews 2020.
Phenotypic changes of HER2-positive breast cancer during and after dual HER2 blockade

Autors:
Brasó-Maristany, F; Griguolo, G; Pascual, T; Vidal, M; Adamo, B;

(...)

Manso, L; Alarcón, J; Martínez, E; Gregorio, S; Gomis, RR.

Referència: Nature Communications 2020.
HER2-Enriched Subtype and ERBB2 Expression in HER2-Positive Breast Cancer Treated with Dual HER2 Blockade

Autors:
Prat, A; Pascual, T; Paré, L; Adamo, B; Brasó-Maristany, F;

(...)

Parker, JS; Dieci, MV; Griguolo, G; Conte, P; Guarneri, V.

Referència: Journal Of The National Cancer Institute 2020.
PAM50MET: A prognostic model based on PAM50 and clinical variables in metastatic hormone receptor (HR)-positive/HER2 negative breast cancer

Autors:
Prat, A; Tsai, Y -H; Pascual, T; Pare, L; Vidal, M;

Adamo, B; Brase, J C; Johnston, S R D; Ciruelos, E M; Parker, J S.

Referència: Annals Of Oncology 2019.

Projectes destacats

HER2-enriched molecular subtype as a predictor of response to dual HER2 blockade.

Investigador/a principal: Aleix Prat

Finançador: Beca Susan Komen (Sede o evento)

Durada: 01/01/2014 - 01/01/2016
Predictores de Respuesta a la Quimioterapia en Cáncer de Mama Triple-Negativo con un Perfil Molecular Basal-like.

Investigador/a principal: Aleix Prat

Finançador: Beca Sandra Ibarra (Sede o evento)

Durada: 01/01/2013 - 01/01/2013
Molecular Quantification of Estrogen Receptor Partners for Endocrine Response Prediction.

Finançador: Universidad de Oslo (Sede o evento)

Durada: 01/01/2012 - 01/01/2016

Maria Jesús Vidal

Grup de recerca

Publicacions destacades

Sentinel node after NeoAdjuvancy in node-positive breast cancer. SANA multicentric study

Efficacy and Safety of Trastuzumab Emtansine Plus Capecitabine vs Trastuzumab Emtansine Alone in Patients With Previously Treated ERBB2 (HER2)-Positive Metastatic Breast Cancer: A Phase 1 and Randomized Phase 2 Trial

Frequency and spectrum of PIK3CA somatic mutations in breast cancer

HER2-enriched subtype and pathological complete response in HER2-positive breast cancer: A systematic review and meta-analysis

Phenotypic changes of HER2-positive breast cancer during and after dual HER2 blockade

HER2-Enriched Subtype and ERBB2 Expression in HER2-Positive Breast Cancer Treated with Dual HER2 Blockade

PAM50MET: A prognostic model based on PAM50 and clinical variables in metastatic hormone receptor (HR)-positive/HER2 negative breast cancer

Projectes destacats

HER2-enriched molecular subtype as a predictor of response to dual HER2 blockade.

Predictores de Respuesta a la Quimioterapia en Cáncer de Mama Triple-Negativo con un Perfil Molecular Basal-like.

Molecular Quantification of Estrogen Receptor Partners for Endocrine Response Prediction.

Subscriu-te a la Newsletter del Clínic